Abeona Therapeutics
ABEO
24 hedge funds and large institutions have $3.62M invested in Abeona Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 12 reducing their positions, and 22 closing their positions.
207% more capital inflows, than outflows
Capital inflows: $1.84M | Capital outflows: $600K
5.25% more ownership
Funds ownership: 14.81% → 20.06% (+5.2%)
43% less funds holding
Funds holding: 42 → 24 (-18)
77% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 22
83% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$832K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$580K |
| 3 |
Cambridge Trust
Cambridge,
Massachusetts
|
+$258K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$140K |
| 5 |
Barclays
London,
United Kingdom
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$256K |
| 2 |
Renaissance Technologies
New York
|
-$115K |
| 3 |
Millennium Management
New York
|
-$46K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$38K |
| 5 |
Kore Private Wealth
New York
|
-$32K |
ABEO Hedge Fund Activity: Q3 2022 in Review
24 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2022, worth a combined $3.62M — down 23% from $4.68M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ABEO and 5 opened new positions — a net loss of 17 holders — while 12 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $832K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $256K sold.
- 24 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2022, down from 42 in Q2 2022.
- Funds reported $3.62M of Abeona Therapeutics stock for Q3 2022, down 23% quarter-over-quarter.
- 5 funds opened new Abeona Therapeutics positions in Q3 2022 and 22 closed out, a net change of -17 holders.
- The largest Abeona Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $832K added.
- The largest Abeona Therapeutics seller in Q3 2022 was D.E. Shaw & Co, an estimated $256K sold.
Based on aggregated 13F filings for Q3 2022.